{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:57:50Z","timestamp":1790582270933,"version":"4.1.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Ascites is a prevalent complication in cases of decompensated liver cirrhosis, having a considerable effect on the quality of life and prognosis of patients. Current treatment methods of ascites in cirrhosis primarily include conventional diuretics, paracentesis, albumin infusion, transjugular intrahepatic portosystemic shunt (TIPS), and liver transplantation. However, these approaches are associated with certain limitations and risks. In recent years, novel therapeutic strategies targeting distinct pathophysiological pathways of ascites have continued to emerge, including sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors, vasopressin analogues, regenerative medicine, and gut microbiota modulation. The present review focuses on emerging pharmacological strategies for ascites in cirrhosis, systematically summarizes their mechanisms of action, and discusses their efficacy, safety, and limitations, while also outlining future research directions.<\/jats:p>","DOI":"10.3389\/fmed.2026.1918993","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:37:10Z","timestamp":1790581030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond conventional treatments: cutting-edge strategies for ascites in cirrhosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Weimiao","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Ningbo University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Fan","sequence":"additional","affiliation":[{"name":"Endoscopy Center, The First Affiliated Hospital of Ningbo University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Ningbo University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Ningbo University","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","article-title":"Guidelines on the management of ascites in cirrhosis","volume":"70","author":"Aithal","year":"2021","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/2040622315580069","article-title":"Management of cirrhotic ascites","volume":"6","author":"Pedersen","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1159\/000502648","article-title":"Diuretic resistance in cardio-nephrology: role of pharmacokinetics, hypochloremia, and kidney remodeling","volume":"44","author":"Masella","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3748\/wjg.v25.i28.3738","article-title":"Current approaches to the management of patients with cirrhotic ascites","volume":"25","author":"Garbuzenko","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/s1665-2681(19)32178-7","article-title":"Pathophysiology, diagnosis and treatment of ascites in cirrhosis","volume":"1","author":"Arroyo","year":"2002","journal-title":"Ann Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s1521-690x(03)00052-6","article-title":"Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites","volume":"17","author":"Cardenas","year":"2003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17474124.2018.1481747","article-title":"Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications","volume":"12","author":"Ponziani","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bcp.2015.09.005","article-title":"SGLT2 inhibitors","volume":"101","author":"Dardi","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis- A unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-25-0015","article-title":"SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis","volume":"2025","author":"Nagayama","year":"2025","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10620-024-08667-4","article-title":"Safety and efficacy of dapagliflozin in recurrent ascites: a pilot study","volume":"70","author":"Singh","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejim.2024.08.012","article-title":"Empagliflozin controls cirrhotic refractory ascites along with improvement of natriuresis and circulatory, cardiac, and renal function: a pilot study","volume":"130","author":"Kalambokis","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1007\/s11606-024-09191-x","article-title":"Empagliflozin in diuretic-refractory ascites (DRAin-em): results of a single-center feasibility study","volume":"40","author":"Hu","year":"2025","journal-title":"J Gen Intern Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2518470","DOI":"10.1001\/jamanetworkopen.2025.18470","article-title":"Sodium-glucose cotransporter 2 inhibitors and serious liver events in patients with cirrhosis","volume":"8","author":"Abu-Hammour","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"106415","DOI":"10.1016\/j.ejps.2023.106415","article-title":"A profile of SGLT-2 inhibitors in hyponatremia: the evidence to date","volume":"184","author":"Tang","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110239","DOI":"10.1016\/j.diabres.2023.110239","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis","volume":"196","author":"Charlwood","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/87551225221074578","article-title":"Analysis of SGLT2 inhibitor therapy and other potential risk factors for the development of bacteremia in patients with urosepsis","volume":"38","author":"Covington","year":"2022","journal-title":"J Pharm Technol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0284","DOI":"10.1097\/XCE.0000000000000284","article-title":"Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis","volume":"12","author":"Deshpande","year":"2023","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13340-020-00473-3","article-title":"COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report","volume":"12","author":"Batista","year":"2021","journal-title":"Diabetol Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11795476221090045","DOI":"10.1177\/11795476221090045","article-title":"The use of SGLT-2 inhibitors coupled with a strict low-carbohydrate diet- A set-up for inducing severe diabetic ketoacidosis","volume":"8","author":"Guirguis","year":"2022","journal-title":"Clin Med Insights Case Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1111\/j.1440-1746.2009.05873.x","article-title":"Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis","volume":"24","author":"Narahara","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0606","article-title":"The application of terlipressin in the management of ascites in liver cirrhosis: current status and prospects","volume":"85","author":"Shen","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1177\/030006051204000512","article-title":"Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2","volume":"40","author":"Huang","year":"2012","journal-title":"J Int Med Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/hep.21901","article-title":"Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome","volume":"46","author":"Krag","year":"2007","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5106958","DOI":"10.1155\/2020\/5106958","article-title":"Role of terlipressin in cirrhotic patients with ascites and without hepatorenal syndrome: a systematic review of current evidence","volume":"2020","author":"Bai","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejim.2011.06.013","article-title":"The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study","volume":"22","author":"Fimiani","year":"2011","journal-title":"Eur J Intern Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"17562848221098253","DOI":"10.1177\/17562848221098253","article-title":"Practice guidance for the use of terlipressin for liver cirrhosis-related complications","volume":"15","author":"Qi","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/ajg.2016.168","article-title":"Outpatient terlipressin infusion for the treatment of refractory ascites","volume":"111","author":"Gow","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/hep.0000000000000820","article-title":"Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study","volume":"80","author":"Terbah","year":"2024","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.cgh.2024.08.010","article-title":"Long-term continuous terlipressin infusion improves cardiac reserve in patients with decompensated cirrhosis","volume":"24","author":"Terbah","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jgh3.12254","article-title":"A retrospective analysis of hyponatremia during terlipressin treatment in patients with esophageal or gastric variceal bleeding due to portal hypertension","volume":"4","author":"Han","year":"2020","journal-title":"JGH Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/jcpt.13057","article-title":"Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin","volume":"45","author":"Pan","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"CD005162","DOI":"10.1002\/14651858.CD005162.pub4","article-title":"Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome","volume":"6","author":"Allegretti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.17235\/reed.2020.7467\/2020","article-title":"Ischemic skin necrosis secondary to the use of terlipressin","volume":"113","author":"Busta Nistal","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"B43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14740338.2020.1734558","article-title":"Development of hyponatremia after terlipressin in cirrhotic patients with acute gastrointestinal bleeding: a retrospective multicenter observational study","volume":"19","author":"Xu","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B44","doi-asserted-by":"publisher","first-page":"116068","DOI":"10.1016\/j.biopha.2023.116068","article-title":"Subcutaneous therapy for portal hypertension: pHIN-214, a partial vasopressin receptor 1A agonist","volume":"171","author":"Castillo","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/hep.28250","article-title":"Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats","volume":"63","author":"Fern\u00e1ndez-Varo","year":"2016","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"F1295","DOI":"10.1152\/ajprenal.90407.2008","article-title":"Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects","volume":"295","author":"Krag","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"115116","DOI":"10.1016\/j.biopha.2023.115116","article-title":"Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites","volume":"165","author":"Fernandez-Varo","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001765","article-title":"OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: a phase 2 randomized trial","author":"Allegretti","year":"2026","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"10253","DOI":"10.3748\/wjg.v21.i36.10253","article-title":"Mesenchymal stem cell therapy for cirrhosis: present and future perspectives","volume":"21","author":"Eom","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13287-022-03001-z","article-title":"Mesenchymal stromal cells: promising treatment for liver cirrhosis","volume":"13","author":"Yao","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1746.2011.07024.x","article-title":"Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients","volume":"27","author":"Zhang","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clinre.2017.11.003","article-title":"Therapeutic efficacy and safety of umbilical cord mesenchymal stem cell transplantation for liver cirrhosis in Chinese population: a meta-analysis","volume":"42","author":"Sang","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/ctr.12179","article-title":"Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: egyptian study","volume":"27","author":"Amin","year":"2013","journal-title":"Clin Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jgh.12029","article-title":"Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis","volume":"28","author":"Wang","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13287-023-03416-2","article-title":"PPARgamma-dependent hepatic macrophage switching acts as a central hub for hUCMSC-mediated alleviation of decompensated liver cirrhosis in rats","volume":"14","author":"Yao","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/liv.12228","article-title":"Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis","volume":"33","author":"Mohamadnejad","year":"2013","journal-title":"Liver Int"},{"key":"B57","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2007.05.018","article-title":"Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats","volume":"133","author":"Piscaglia","year":"2007","journal-title":"Gastroenterology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s12072-022-10314-x","article-title":"Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT","volume":"16","author":"Venkitaraman","year":"2022","journal-title":"Hepatol Int"},{"key":"B59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cgh.2020.02.022","article-title":"Multiple cycles of granulocyte colony-stimulating factor increase survival times of patients with decompensated cirrhosis in a randomized trial","volume":"19","author":"De","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3000605231207064","DOI":"10.1177\/03000605231207064","article-title":"Role of granulocyte colony stimulating factor in the treatment of cirrhosis of liver: a systematic review","volume":"51","author":"Rajpurohit","year":"2023","journal-title":"J Int Med Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/hep.29763","article-title":"Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: a randomized trial","volume":"68","author":"Verma","year":"2018","journal-title":"Hepatology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/liv.13923","article-title":"Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis","volume":"39","author":"Anand","year":"2019","journal-title":"Liver Int"},{"key":"B63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/scrt459","article-title":"Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease","volume":"5","author":"Salama","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s2468-1253(17)30326-6","article-title":"Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial","volume":"3","author":"Newsome","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jceh.2019.05.003","article-title":"Granulocyte colony-stimulating factor use in decompensated cirrhosis: lack of survival benefit","volume":"10","author":"Philips","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4240\/wjgs.v15.i4.655","article-title":"Endoscopic ultrasound-guided intraportal injection of autologous bone marrow in patients with decompensated liver cirrhosis: a case series","volume":"15","author":"Zheng","year":"2023","journal-title":"World J Gastrointest Surg"},{"key":"B67","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3892\/etm.2022.11570","article-title":"Therapeutic effect of autologous bone marrow cells injected into the liver under the guidance of B-ultrasound in the treatment of HBV-related decompensated liver cirrhosis","volume":"24","author":"Li","year":"2022","journal-title":"Exp Ther Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"B69","doi-asserted-by":"publisher","first-page":"25001","DOI":"10.1038\/srep25001","article-title":"Alteration of the serum microbiome composition in cirrhotic patients with ascites","volume":"6","author":"Santiago","year":"2016","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/br.2026.2101","article-title":"Integrated analysis of gut microbiota structure and metabolic function in patients with cirrhosis and refractory ascites","volume":"24","author":"Chen","year":"2026","journal-title":"Biomed Rep"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1717696","DOI":"10.3389\/fcimb.2025.1717696","article-title":"Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications","volume":"15","author":"Chang","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.30349","article-title":"Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis","volume":"70","author":"Mu\u00f1oz","year":"2019","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.1096\/fj.201901327R","article-title":"Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis","volume":"33","author":"Juanola","year":"2019","journal-title":"FASEB J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3748\/wjg.v26.i2.199","article-title":"Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study","volume":"26","author":"Lv","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12072-020-10117-y","article-title":"Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis","volume":"15","author":"Zeng","year":"2021","journal-title":"Hepatol Int"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.4254\/wjh.v14.i8.1667","article-title":"Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: a pilot randomized controlled trial","volume":"14","author":"Maslennikov","year":"2022","journal-title":"World J Hepatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/liv.12539","article-title":"Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites","volume":"34","author":"Rinc\u00f3n","year":"2014","journal-title":"Liver Int"},{"key":"B78","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/jcm13030919","article-title":"Efficacy and safety of a probiotic containing Saccharomyces boulardii CNCM I-745 in the treatment of small intestinal bacterial overgrowth in decompensated cirrhosis: randomized, placebo-controlled study","volume":"13","author":"Efremova","year":"2024","journal-title":"J Clin Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/liv.12566","article-title":"VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis","volume":"35","author":"S\u00e1nchez","year":"2015","journal-title":"Liver Int"},{"key":"B80","doi-asserted-by":"publisher","first-page":"45712","DOI":"10.1038\/srep45712","article-title":"Fermented milk containing lactobacillus paracasei subsp. Paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride","volume":"7","author":"S\u00e1nchez","year":"2017","journal-title":"Sci Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1918993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:37:12Z","timestamp":1790581032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1918993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":80,"alternative-id":["10.3389\/fmed.2026.1918993"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1918993","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1918993"}}